Halozyme's technology turns IV drugs into quick injections — royalties from many blockbusters.
Halozyme Therapeutics, Inc. (HALO) is expected to report earnings on Monday, November 2, 2026, after the close. Estimated release time 16:06 ET. Consensus EPS estimate is $2.28.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $1.79 | $1.96 | +9.5% | $481.00M |
| 2026-05-11 | Mar 2026 qtr | $1.55 | $1.27 | — | $376.71M |
| 2026-02-17 | Dec 2025 qtr | $2.15 | $-0.24 | — | $451.77M |
| 2025-10-03 | Sep 2025 qtr | — | $1.49 | — | $354.26M |
| 2025-08-05 | Jun 2025 qtr | $1.23 | $1.36 | +10.6% | $325.72M |
| 2025-05-06 | Mar 2025 qtr | $0.95 | $0.96 | +1.1% | $264.86M |
| 2025-02-18 | Dec 2024 qtr | $1.17 | $1.08 | -7.7% | $298.01M |
| 2024-10-31 | Sep 2024 qtr | $0.98 | $1.08 | +10.2% | $290.08M |
HALO has beaten consensus EPS in 4 of its last 5 scored quarters.
See HALO on the live calendar →